[Form 4] Rein Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 – Rein Therapeutics, Inc. (RNTX)

Director Josef H. von Rickenbach was granted a stock option for 17,500 common shares on 07/23/2025 at an exercise price of $1.55. The option vests in full on the earlier of 07/23/2026 or the date of the company’s 2026 annual meeting, subject to continued board service, and expires on 07/22/2035. No open-market purchases or sales of common stock were reported, and the director’s derivative ownership now stands at 17,500 options held directly.

This appears to be routine board compensation: it modestly increases potential dilution but strengthens insider alignment. The filing discloses no changes to previously reported share ownership and contains no fundamental financial information.

Insights

Securities Analyst

TL;DR: Routine option grant; neutral for valuation, negligible dilution, aligns director incentives.

The 17,500-share option equals a tiny fraction of Rein Therapeutics’ float and does not indicate insider buying or selling pressure. With a 10-year term and $1.55 strike, the grant aligns the director with long-term share performance but has immaterial EPS impact. No red flags or bullish signals emerge; investors can treat this as standard governance disclosure rather than a trading catalyst.

Corporate Governance Expert

TL;DR: Standard director compensation, supports retention; corporate-governance neutral.

The single-tranche, one-year vesting schedule is typical for small-cap boards and encourages continued service through the 2026 AGM. The absence of performance conditions is commonplace but could be tightened for stronger pay-for-performance linkage. Overall governance posture remains unchanged.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

VON RICKENBACH JOSEF H

(Last) (First) (Middle)

C/O REIN THERAPEUTICS, INC

12407 N. MOPAC EXPY. SUITE 250 #390

(Street)

AUSTIN TX 78758

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rein Therapeutics, Inc. [ RNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.55	07/23/2025		A		17,500		(1)	07/22/2035	Common Stock	17,500	$0.00	17,500	D

Explanation of Responses:

1. This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.

	/s/ Brian Windsor, attorney-in-fact for Josef H. von Rickenbach	07/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Rein Therapeutics (RNTX) file with the SEC on 07/23/2025?

Form 4 reporting a stock-option grant to director Josef H. von Rickenbach.

How many options were granted and at what exercise price?

The director received 17,500 options with a strike price of $1.55 per share.

When do the RNTX options vest and expire?

They vest on the earlier of 07/23/2026 or the 2026 annual meeting and expire on 07/22/2035.

Were any Rein Therapeutics common shares bought or sold?

No. The filing shows only a derivative (option) acquisition; no common-stock transactions occurred.

Does the grant materially dilute existing RNTX shareholders?

Dilution is immaterial; 17,500 shares represent a very small portion of the company’s total outstanding shares.